Physician profile
Steven M Sutherland
NPI 1720098213
$168,916.88
in general payments reported to CMS, 2019-2025
29 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $1,994 · 2021: $31K · 2022: $28K · 2023: $24K · 2024: $21K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Honoraria: $29K · Food and Beverage: $7,320 · Travel and Lodging: $6,663 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,500.00 |
| Honoraria | $28,750.00 |
| Food and Beverage | $7,319.55 |
| Travel and Lodging | $6,663.22 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $125,407.42 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $37,009.21 | 2019-2023 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,272.40 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $848.79 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $589.34 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $433.51 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $397.99 | 2022-2025 | Auvelity |
| Corium, LLC | $336.90 | 2021-2025 | Azstarys |
| Alkermes, INC. | $324.57 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $258.03 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $245.33 | 2019-2025 | Trintellix |
| Tris Pharma INC | $235.21 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Bausch Health US, LLC | $227.88 | 2020-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $197.35 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $161.29 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $135.08 | 2019-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $121.32 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $114.97 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $109.73 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $80.15 | 2021-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $75.91 | 2021-2024 | Xelstrym |
| Eisai INC. | $75.60 | 2021 | |
| Idorsia Pharmaceuticals US INC | $67.31 | 2022-2024 | Quviviq |
| Allergan, INC. | $60.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.60 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $36.04 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.68 | 2025 | Rejoyn |
| Avanir Pharmaceuticals, INC. | $19.45 | 2019 | |
| Pfizer INC. | $17.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.